That graph is showing that PME's revenue grew at 27% p.a. which is fantastic.
PME is a fabulous business. It has not had a capital raise in ten years. Is debt free, generates a ROE of 38% and grows its earnings annually at an average rate of 36% p.a.
If Mach7 can generate compound sales growth of a similar order then the metrics will end up being very similar and the Mach7 business model will be confirmed.
I believe that Mike Lampron has set Mach7 up for success and the timing of bigger hospital budgets chasing efficiencies and the big build up of the Mach7 Sales Team will be a very fruitful coincidence.
I invested in Mach7 because I believe it can achieve similar growth to PME. I came across M7T when researching what other ASX listed companies were in the medical technology space and M7T ticked most of the boxes on my list. I was latterly pleasantly surprised to read you were a very enthusiastic M7T shareholder and also a FID shareholder which I like very much as well.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)